Literature DB >> 14551747

Cytokines IL-1 alpha, IL-6, and GM-CSF constitutively secreted by oral squamous carcinoma induce down-regulation of CD80 costimulatory molecule expression: restoration by interferon gamma.

Giovana R Thomas1, Zhong Chen, Elena Leukinova, Carter Van Waes, Judy Wen.   

Abstract

We previously characterized the expression of CD80 in different murine head and neck squamous cell carcinoma (HNSCC) clones derived following tumor progression in the absence of T cell-mediated immunity in severe combined immunodeficient (SCID) mice. We found that HNSCCs that did not express CD80 grew as progressors, while those that expressed CD80 were regressors when grown in immune-competent animals. In the present study, we characterized expression of a repertoire of immunoregulatory cytokines in these HNSCC lines, and found that HNSCCs that express cytokines IL-1 alpha, IL-6, and GM-CSF do not express CD80, suggesting the hypothesis that these cytokines may down-modulate expression of CD80. Cytokine-conditioned medium from progressor HNSCC and recombinant IL-1 alpha, IL-6, and GM-CSF caused a reduction of CD80 expression in regressor HNSCCs without affecting proliferation. Conversely, the decrease in CD80 expression in progressor HNSCCs could be restored by IFN-gamma, a known inducer of CD80 expression. These data strongly suggest that high levels of cytokines IL-1 alpha, IL-6, and GM-CSF expressed by tumor cells can down-regulate CD80 expression in HNSCC, and that IFN-gamma can independently stimulate expression. These data provide evidence for a novel mechanism of cytokine-mediated down-modulation of CD80 during malignant progression of HNSCC that can be restored by IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14551747     DOI: 10.1007/s00262-003-0433-4

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  12 in total

1.  Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer.

Authors:  Athanassios Argiris; Steve C Lee; Trevor Feinstein; Sufi Thomas; Barton F Branstetter; Raja Seethala; Lin Wang; William Gooding; Jennifer R Grandis; Robert L Ferris
Journal:  Oral Oncol       Date:  2011-09-01       Impact factor: 5.337

2.  Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells.

Authors:  Han-Ching Tseng; Aida Arasteh; Avina Paranjpe; Antonia Teruel; Wendy Yang; Armin Behel; Jackelyn A Alva; Gina Walter; Christian Head; Tomo-o Ishikawa; Harvey R Herschman; Nicholas Cacalano; April D Pyle; No-Hee Park; Anahid Jewett
Journal:  PLoS One       Date:  2010-07-16       Impact factor: 3.240

3.  Development of Cancer Immunotherapies.

Authors:  Diana C DeLucia; John K Lee
Journal:  Cancer Treat Res       Date:  2022

4.  Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells.

Authors:  Rania H Younis; Kyu Lee Han; Tonya J Webb
Journal:  J Immunol       Date:  2016-01-06       Impact factor: 5.422

5.  Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer.

Authors:  Nichole R Dean; J Robert Newman; Emily E Helman; Wenyue Zhang; Seena Safavy; D M Weeks; Mark Cunningham; Linda A Snyder; Yi Tang; Li Yan; Lacey R McNally; Donald J Buchsbaum; Eben L Rosenthal
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

6.  IL-10 in the microenvironment of HNSCC inhibits the CpG ODN induced IFN-α secretion of pDCs.

Authors:  Karl-Ludwig Bruchhage; Sabrina Heinrichs; Barbara Wollenberg; Ralph Pries
Journal:  Oncol Lett       Date:  2018-01-11       Impact factor: 2.967

Review 7.  Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer.

Authors:  Ruth J Davis; Carter Van Waes; Clint T Allen
Journal:  Oral Oncol       Date:  2016-05-20       Impact factor: 5.337

8.  Tumor induced inactivation of natural killer cell cytotoxic function; implication in growth, expansion and differentiation of cancer stem cells.

Authors:  Anahid Jewett; Han-Ching Tseng
Journal:  J Cancer       Date:  2011-08-10       Impact factor: 4.207

Review 9.  Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches.

Authors:  Clint T Allen; Paul E Clavijo; Carter Van Waes; Zhong Chen
Journal:  Cancers (Basel)       Date:  2015-12-09       Impact factor: 6.639

Review 10.  Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies-A review.

Authors:  Sandeep Nayar; Prokar Dasgupta; Christine Galustian
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.